BIAL Biotech to be based in Cambridge, Massachusetts and will be a Research Center of Excellence dedicated to genetically-defined Parkinson’s disease
LTI-291 clinical program and other research programs in Parkinson’s disease acquired from Lysosomal Therapeutics, Inc.
R&D team led by Peter Lansbury, professor of neurology at Harvard Medical School
Investment may add up to 130 million dollars depending on the accomplishment of downstream development, and several regulatory and commercial milestones
BIAL, a pharmaceutical company based in Portugal with locations across Europe and dedicated to R&D in CNS diseases, announced today that it has established a new affiliate in the United States of America, BIAL Biotech Investments Inc. (BIAL Biotech). This new research center focused on genetically-defined Parkinson’s disease is based in Cambridge, Massachusetts, a prominent biotech hub in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005323/en/
Simultaneously, BIAL announced that it has acquired worldwide rights